AIMS Human laboratory studies have contributed extensively in the research and development of novel medications to treat alcohol use disorder (AUD). Alcohol tolerance may represent one additional variable that can be utilized to expand the understanding of the AUD wide phenotypic profile and provide support to the medication development process. Tolerance is characterized as an individual's subjective response to alcohol and has been recognized as a predictor of AUD progression. Tolerance can be evaluated both by self-reported response (e.g. assessments) and objective measurements (e.g. motor impairment); as such, it represents an exploitable variable in the field of alcohol research. METHODS This Narrative Review focuses on the use of alcohol tolerance, specifically within alcohol laboratory studies, for medication development. It seeks to identify a research gap and a research opportunity in clinical studies to evaluate biobehavioral responses captured in order to develop medications to treat AUD. RESULTS Alcohol tolerance may provide additional information on the safety and tolerability of medications to treat AUD, in particular, when novel medications are co-administered with alcohol within the AUD population. CONCLUSIONS As such, alcohol tolerance represents an additional outcome that may be included in randomized clinical trial (RCT) protocols designed for developing AUD pharmacotherapies.

中文翻译：

---

人类实验室研究中的酒精耐受性，以开发治疗酒精使用障碍的药物。


目的 人类实验室研究为治疗酒精使用障碍 (AUD) 的新型药物的研发做出了广泛贡献。酒精耐受性可能是一个额外的变量，可用于扩大对 AUD 广泛表型谱的理解，并为药物开发过程提供支持。耐受性是个体对酒精的主观反应，并被认为是 AUD 进展的预测指标。耐受性可以通过自我报告的反应（例如评估）和客观测量（例如运动障碍）来评估；因此，它代表了酒精研究领域的一个可利用变量。方法 本叙述综述重点关注酒精耐受性（特别是在酒精实验室研究中）用于药物开发的用途。它旨在确定临床研究中的研究差距和研究机会，以评估捕获的生物行为反应，从而开发治疗 AUD 的药物。结果酒精耐受性可以提供有关治疗 AUD 的药物的安全性和耐受性的额外信息，特别是当 AUD 人群中同时使用新药物和酒精时。结论 因此，酒精耐受性代表了一个额外的结果，可以包含在为开发 AUD 药物疗法而设计的随机临床试验 (RCT) 方案中。